Alzheimer’s disease is a serious brain condition that slowly destroys memory and thinking ability. One of the key changes in the brains of people with Alzheimer’s involves a protein called tau.
In a healthy brain, tau helps keep nerve cells stable and working properly. It acts like a support system inside the cells. But in Alzheimer’s disease, tau proteins lose their normal shape.
They twist into abnormal forms and stick together, forming clumps inside brain cells. These clumps spread through the brain and damage the cells, eventually causing them to die.
Doctors and scientists have been searching for ways to detect these changes in living people. One important tool is a special brain scan called PET, short for positron emission tomography. This scan uses a small amount of a safe radioactive substance that attaches to certain proteins in the brain.
When the scan is done, it produces images that show where these proteins are located. PET scans have become very valuable for studying Alzheimer’s disease because they allow doctors to “see” the disease process instead of only guessing from symptoms.
In recent years, PET scans designed to detect tau have been used more often in hospitals and research centers.
These scans can help doctors confirm a diagnosis, estimate how far the disease has progressed, and decide whether a patient might benefit from new treatments being tested. They are also used in clinical trials to track whether experimental drugs are working.
However, scientists have discovered an important problem. The most common substance used in tau PET scans, called flortaucipir, does not always stick only to tau. Sometimes it attaches to other things in the brain as well.
This can cause the scan to show signals even when tau is not the main cause. This issue is especially noticeable in brain disorders that are not Alzheimer’s disease but still involve abnormal proteins.
To better understand this problem, researchers at the University of California, San Francisco carried out a detailed study. They used a rare approach that combined brain scans taken while patients were alive with careful examination of brain tissue after death.
This allowed them to compare the scan images with the real physical changes in the brain at the exact same locations.
Using advanced computer methods and artificial intelligence, the scientists lined up the scans and tissue samples very precisely. They compared thousands of tiny points in the brain one by one. This gave them a much clearer picture than earlier studies.
The team looked at several features in the brain that might affect the scan signal. They examined the amount of abnormal tau, the presence of iron deposits, and signs of inflammation caused by special support cells in the brain called astrocytes. These cells become active when the brain is under stress or injury.
The results showed that in some people, especially those with conditions other than Alzheimer’s disease, the scan signal was influenced more by iron or inflammation than by tau itself. In other words, the scan sometimes “lit up” for reasons unrelated to the tau tangles doctors were trying to measure.
This discovery helps explain why some scans appear confusing or show unexpected results. It also means that doctors need to be careful when interpreting these images, especially when the signal is weak or unclear. Understanding what the scan is truly showing can prevent mistakes in diagnosis and treatment decisions.
Importantly, the researchers say this does not mean tau PET scans are useless. Instead, the findings help improve how the scans should be read. By knowing that other factors can affect the signal, doctors can make more accurate judgments about a patient’s condition.
The study may also help scientists develop better scanning substances in the future that attach only to tau and nothing else. Such improvements could make Alzheimer’s diagnosis earlier and more precise, which is crucial as new treatments are being developed.
Alzheimer’s disease affects millions of families worldwide, and early detection is one of the best hopes for slowing its progress. This research shows that even powerful medical tools have limits, but understanding those limits can lead to better care and better science.
If you care about Alzheimer’s disease, please read studies about vitamin D deficiency linked to Alzheimer’s and dementia, and strawberries can be good defence against Alzheimer’s.
For more health information, please see recent studies about foods that reduce Alzheimer’s risk, and oral cannabis extract may help reduce Alzheimer’s symptoms.
The study is published in Acta Neuropathologica.
Copyright © 2026 Knowridge Science Report. All rights reserved.
